Michele LaRussa

Michele LaRussa has an extensive background in regulatory affairs and pharmaceutical experience spanning over 30 years. Michele is currently serving as the Chief Regulatory Officer at SFJ Pharmaceuticals, Inc. starting in July 2022. Prior to this role, they founded their own consulting firm, LaRussa Pharma Consulting LLC, in September 2021, where they provided executive regulatory expertise. Michele has led multiple interactions with health authorities such as the FDA, EMA, and PMDA, with a focus on therapeutic areas including ophthalmology and dermatology.

Before their consulting work, Michele held the position of Chief Regulatory Officer at Atox Bio from May 2019 to April 2022. Michele also served as the VP and Global Head of Regulatory Affairs at Liquidia Technologies from November 2018 to May 2019 and as the SVP and Global Head of Regulatory Affairs and Quality Assurance at Kala Pharmaceuticals from October 2016 to October 2018.

Prior to their roles in the biopharmaceutical industry, Michele held leadership positions in regulatory affairs at GSK from July 2012 to September 2016, Allergan from September 2007 to July 2012, Novartis from 1994 to 2007, and Bausch & Lomb from 1992 to 1994.

Throughout their career, Michele has demonstrated their ability to lead, build, mentor, and develop teams of various sizes. Their expertise and experience in regulatory affairs make their a valuable asset in the pharmaceutical industry.

Michele LaRussa attended the University of South Florida from 1988 to 1992. However, no specific degree or field of study information is available for this period.